Literature DB >> 6854021

IgA blocks IgM and IgG-initiated immune lysis by separate molecular mechanisms.

J M Griffiss, D K Goroff.   

Abstract

Circulating IgA which does not bind the first component of complement (C) and does not activate the classical C pathway, blocks the initiation of C-mediated immune effector mechanisms. In at least two clinical situations, epidemic meningococcal disease and severe hepatic dysfunction, IgA blockade of one such mechanism, immune lysis, results in susceptibility to hematogenous bacterial dissemination. The presence of strain-specific IgM, but not IgG, in the sera of susceptibles at the time of dissemination suggested that IgA blockade of IgM-initiated lysis involves a separate mechanism more sensitive to quantitative changes than that involved in IgA blockade of IgG-initiated lysis. We report here that whereas IgA blockade of IgG-initiated immune lysis is a competitive function of the ratio of IgA to IgG, the blocking of IgM-initiated lysis is a noncompetitive function of the ratio of IgA to target cells, independent of the concentration of IgM. In the presence of sufficient IgA to saturate binding sites, IgM is an impotent bystander unable to compete for sites or initiate lysis. Therefore, C-mediated effector mechanisms are more sensitive to quantitative changes in circulating IgA and target cells (binding sites) in the absence of IgG than in its presence. Neither mechanism appears related to binding kinetics.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6854021

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  47 in total

1.  T and B cell responses following immunization with tetanus toxoid in IgA nephropathy.

Authors:  F Fortune; M Courteau; D G Williams; T Lehner
Journal:  Clin Exp Immunol       Date:  1992-04       Impact factor: 4.330

2.  Opsonic effect of jacalin and human immunoglobulin A on type II group B streptococci.

Authors:  N R Payne; N F Concepcion; B F Anthony
Journal:  Infect Immun       Date:  1990-11       Impact factor: 3.441

Review 3.  The structure and function of human IgA.

Authors:  M A Kerr
Journal:  Biochem J       Date:  1990-10-15       Impact factor: 3.857

4.  Acellular pertussis vaccines and complement killing of Bordetella pertussis.

Authors:  Alison A Weiss; Angela K Patton; Scott H Millen; Swei-Ju Chang; Joel I Ward; David I Bernstein
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

5.  Importance of complement source in measuring meningococcal bactericidal titers.

Authors:  G F Santos; R R Deck; J Donnelly; W Blackwelder; D M Granoff
Journal:  Clin Diagn Lab Immunol       Date:  2001-05

6.  Bactericidal and cross-protective activities of a monoclonal antibody directed against Neisseria meningitidis NspA outer membrane protein.

Authors:  N Cadieux; M Plante; C R Rioux; J Hamel; B R Brodeur; D Martin
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

7.  Bactericidal antibody responses of juvenile rhesus monkeys immunized with group B Neisseria meningitidis capsular polysaccharide-protein conjugate vaccines.

Authors:  W D Zollinger; E E Moran; S J Devi; C E Frasch
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

Review 8.  Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides.

Authors:  J E van Dam; A Fleer; H Snippe
Journal:  Antonie Van Leeuwenhoek       Date:  1990-06       Impact factor: 2.271

9.  Anti-Gal binds to pili of Neisseria meningitidis: the immunoglobulin A isotype blocks complement-mediated killing.

Authors:  R M Hamadeh; M M Estabrook; P Zhou; G A Jarvis; J M Griffiss
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

10.  Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine.

Authors:  E Rosenqvist; E A Høiby; E Wedege; K Bryn; J Kolberg; A Klem; E Rønnild; G Bjune; H Nøkleby
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.